NITED STATES PATENT AND TRADEMA

In re Patent Application of

Atty Dkt. 117-328 C#

O'CONNOR et al.

Group Art Unit:

Serial No. 09/701,080

Examiner:

Filed: February 27, 2001

Date: October 15, 2001

OCT 1 5 200

POLYPEPTIDES FROM CREB BINDING PROTEIN AND RELATED PROTEIN Title:

P300 FOR USE IN TRANSCRIPTIONAL REGULATION

Assistant Commissioner for Patents

Washington, DC 20231

Sir:

RESPONSE TO NOTIFICATION OF A DEFECTIVE RESPONSE AND

NOTIFICATION TO COMPLY

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below: Total effective claims after amendment 0 minus highest number previously paid for 20 (at least 20) = 0 x \$ 18.00	\$	0.00
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	\$	0.00
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$	0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$	0.00
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00
First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) Please enter the previously unentered , filed Submission attached	\$	0.00
Subtotal	\$	0.00
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith	-\$	0.00
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00
Assignment Recording Fee (\$40.00)	\$	0.00
Other:		0.00
TOTAL FEE ENCLOSED	\$	0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100 MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

567890

	IN THE TEL	STATES PAT	ENT AND TRA	DEMA	HICE IN	"UITTO	131	<u> </u>
In re Patent Application of		Atty Dkt	: 117-326	/0	ILE AS	\	1	$D_{\alpha} \propto 1$
O'CONNOR et al.		Group Art Unit:	C# M#	TO	ص ع 1 5 200 1 ع	<u> </u>	#	BON -
Serial No. 09/701,080		Examiner:		(P. 001	OFFIC	<i>?)</i>	1:	
Filed: February 27, 200	1	Date:	October 15, 2	2001 FAV	TRADEMARK			
Title: POLYPEPTIDES FI	ROM CREB BINDIN TRANSCRIPTIONA	IG PROTEIN AND L REGULATION	RELATED PRO	DTEIN				
Assistant Commissioner for Washington, DC 20231								
Sir:	RESPONSE TO N	NOTIFICATION	ON TO COMPL	.Υ			hereb	v
incorporated by reference signature thereon.	and the signature	e below serves a	s the signature	to the atta	achment in t	he absence	e of any	other
Fees are attached as call Total effective claims after previously paid for 2			ghest number x \$ 18.00				\$	0.00
Independent claims after a previously paid for 3	amendment (at least 3) =		ghest number x \$ 84.00				\$	0.00
If proper multiple depende	ent claims now add	ded for first time	, add \$280.00 ((ignore imp	oroper)		\$	0.00
Petition is hereby made to paper and attachment(s) (\$	extend the currer	nt due date so a 400.00/2 month:	s to cover the f s; \$920.00/3 m	iling date o	of this	,	\$	0.00
Terminal disclaimer enclo					•		\$	0.00
First/second submiss Please enter the place of Submission attack	previously unenter		to 37 CFR 1.12	29(a) (\$740	0.00)		\$	0.00
☐ Submission attack	nea					Subtotal	\$	0.00
If "small entity," then ente	er half (1/2) of subt ms "small entity" s	otal and subtractionstatus. Status. Status.	t atement filed he	erewith			-\$.	0.00
Rule 56 Information Discl	osure Statement F	Filing Fee (\$180	.00)				\$	0.00
Assignment Recording Fe							\$	0.00
Other:								0.00
				тс	TAL FEE E	ENCLOSED	\$	0.00
The Commissioner is her should have been filed he 14-1140. A <u>duplicate</u> cop	erewith (or with an	y paper hereafte	ciency in the fe er filed in this a	e(s) filed, o pplication t	or asserted by this firm)	to be filed, o to our Acco	or whic ount No	h).
1100 North Glebe Road, Arlington, Virginia 22201- Telephone: (703) 816-40	-4714		ON & VANDER tty: Mary J. W		No. 32,955	,		,
Facsimile: (703) 816-410			1	1	į			

MJW:tat

DISK TOSTIC DATE:

BEST AVAILABLE COPY

United States Patent and Trademark Office Commissioner for Patents, Box on, D.C FIRST NAMED APPLICANT 09/701080 O CONNOR 117-328 INTERNATIONAL APPLICATION NO **NIXON & VANDERHYE** DATES DOCKETED PCT/GB99/01668 8TH FLOOR 1100 NORTH GLEBE ROAD I.A. FILING DATE ARLINGTON, VA 22201 26 MAY 99 26 MAY 98 14 SEP 2001 NOTIFICATION OF A DEFECTIVE RESPONSE The request for an extension of time (37 CFR 1.136(a)) filed because the required fee is missing/insufficient. Extension of time fees are listed at 37 CFR 1.17(a)(1)-(a)(5).Applicant's response filed was received in the Office after the expiration of the period for response set in the Office notification mailed application will become abandoned unless applicant obtains an extension of time to reply to the last Office notification under 37 CFR 1.136(a). Applicant's response filed is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS (Form PCT/DO/EO/905) mailed have not been completed. Translation of the international application into English. which is defective for the reasons indicated on the attached Notice of Defective Translation. Processing fee (37 CFR 1.492(f)). Oath or Declaration of inventors(s). not in compliance with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917. Surcharge (37 CFR 1.492(e)). Sequence Listing. not in compliance with 37 CFR 1.821-1.825 for the reasons indicated on the attached PCT/DO/EO/920. Additional claim fees. Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements (Form DO/EO/905), whichever is the longer. No extension of this time limit may be granted under 37 C.F.R. § 1.136, but the period for response set in the Notification of Missing Requirements (Form DO/EO/905) may be extended under 37 C.F.R. § 1.136(a). Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)

Enclosed: PCT/DO/EO/917 Notice of Defective Translation CT/DO/EO/920

Telephone: 703-305-3736

FORM PCT/DO/EO/916 (March 2001)



Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT ATTY, DOCKET NO.		
09/701080	O CONNOR	117-328	
	[INTERNATIONAL A	APPLICATION NO.
NIXON & VANDERHYE 8TH FLOOR		PCT/GB9	9/01668
1100 NORTH GLEBE ROAD ARLINGTON, VA 22201] [I.A. FILING DATE	PRIORITY DATE
ARCINGTON, VA 22201	• .	26 MAY 99	26 MAY 98
 		. DATE MAILED:	14 SEP 2001

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

		·
	×	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
	H	This application does not contain, a "Sequence Listing" as a separate part of the
		disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
	П	A copy of the "Sequence Listing" in computer readable format has not been submitted as
,	ب	required by 37 CFR 1.821(e).
	×	A copy of the "Sequence Listing" in computer readable form has been submitted. The
		content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
	\Box	The computer readable form that has been filed with this application has been found to be
		damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A
		substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
		The paper copy or compact disc of the "Sequence Listing" is not the same as the
		computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
		Other:
APPLI	CA	NT MUST PROVIDE:
	П	An initial or substitute computer readable form (CRF) of the "Sequence Listing."
	H	An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
		amendment directing its entry into the specification.
	×	A statement that the contents of the paper or compact disc and the computer readable form
	<u> </u>	are the same and, where applicable, include no new matter, as required by 37 CFR
		1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR Q		STIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
	(7	703) 308-4216, for Rules interpretation,
	•	703) 308-4212, for CRF submission help,
	(7	703) 287-0200, for Patentin software help.
		Vonda M. Wallace // W

Telephone: 703-305-3736

FORM PCT/DO/EO/920 (March 2001)